ArticleKidney international reports2025
Obinutuzumab in Rituximab-Resistant Podocytopathies: A Single-Center Experience.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Global trends and knowledge mapping of steroid-resistant nephrotic syndrome research: a bibliometric analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Reassessing the role of kidney biopsy in early idiopathic steroid-resistant nephrotic syndrome among children and young adults.Pediatric nephrology (Berlin, Germany) · 2026Article
- Kidney Survival in Children With Steroid-Resistant Nephrotic Syndrome Treated by Rituximab.Kidney international reports · 2026Article
- B-cell-targeting therapies in podocytopathies.Pediatric nephrology (Berlin, Germany) · 2026Review
- Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study.Transplantation direct · 2026Article
- Obinutuzumab as a Rescue and Maintenance Strategy in Children with Difficult-to-Treat Nephrotic Syndrome After Rituximab-Based Treatment Failure or Intolerance: A Preliminary Single-Center Real-World Retrospective Study.Drug design, development and therapy · 2026Article
- Successful use of obinutuzumab in focal segmental glomerulosclerosis with inadequate response to rituximab: a case report.Frontiers in nephrology · 2026Article
- Does baseline proteinuria affect the efficacy of obinutuzumab in patients with primary membranous nephropathy and minimal change disease? a single-center retrospective study.Frontiers in pharmacology · 2026Article
- Successful Therapy with Obinutuzumab in a Toddler with Primary Multidrug-Resistant Nephrotic Syndrome.Journal of clinical medicine · 2025Article
- Juvenile-onset Systemic Lupus Erythematosus: Recent Advances in Pathogenesis and Treatment.Current rheumatology reports · 2025Review
- Daratumumab combined with anti-CD20 therapy in pediatric and adult refractory idiopathic nephrotic syndrome: single-center experience.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.